Evidence map›Paper›PMID 34341435›Full record

ArticleScientific reports2021

Plasma expression of microRNA-425-5p and microRNA-451a as biomarkers of cardiovascular disease in rheumatoid arthritis patients.

Delia Taverner, Dídac Llop, Roser Rosales, Raimon Ferré, Luis Masana, Joan-Carles Vallvé, Silvia Paredes

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Delia Taverner *Sección de Reumatología, Hospital Universitario Sant Joan, Reus, Catalonia, Spain.
Dídac Llop *Unitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Roser RosalesUnitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Raimon FerréUnitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Luis MasanaUnitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Joan-Carles VallvéUnitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Catalonia, Spain. jc.vallve@urv.cat.
Silvia ParedesSección de Reumatología, Hospital Universitario Sant Joan, Reus, Catalonia, Spain.
Universidad Rovira i Virgili · ESHospital Universitari Sant Joan de Reus · ESCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To validate in a cohort of 214 rheumatoid arthritis patients a panel of 10 plasmatic microRNAs, which we previously identified and that can facilitate earlier diagnosis of cardiovascular disease in rheumatoid arthritis patients. We identified 10 plasma miRs that were downregulated in male rheumatoid arthritis patients and in patients with acute myocardial infarction compared to controls suggesting that these microRNAs could be epigenetic biomarkers for cardiovascular disease in rheumatoid arthritis patients. Six of those microRNAs were validated in independent plasma samples from 214 rheumatoid arthritis patients and levels of expression were associated with surrogate markers of cardiovascular disease (carotid intima-media thickness, plaque formation, pulse wave velocity and distensibility) and with prior cardiovascular disease. Multivariate analyses adjusted for traditional confounders and treatments showed that decreased expression of microRNA-425-5p in men and decreased expression of microRNA-451 in women were significantly associated with increased (β = 0.072; p = 0.017) and decreased carotid intima-media thickness (β = -0.05; p = 0.013), respectively. MicroRNA-425-5p and microRNA-451 also increased the accuracy to discriminate patients with pathological carotid intima-media thickness by 1.8% (p = 0.036) in men and 3.5% (p = 0.027) in women, respectively. In addition, microRNA-425-5p increased the accuracy to discriminate male patients with prior cardiovascular disease by 3% (p = 0.008). Additionally, decreased expression of microRNA-451 was significantly associated with decreased pulse wave velocity (β = -0.72; p = 0.035) in overall rheumatoid arthritis population. Distensibility showed no significant association with expression levels of the microRNAs studied. We provide evidence of a possible role of microRNA-425-5p and microRNA-451 as useful epigenetic biomarkers to assess cardiovascular disease risk in patients with rheumatoid arthritis.

Indexed as

Arthritis, RheumatoidBiomarkersCardiovascular DiseasesCarotid Intima-Media ThicknessMicroRNAsAgedFemaleHumansMaleMiddle AgedPulse Wave AnalysisBiomarkersMicroRNAsMIRN451 microRNA, human

Identifiers

PMID34341435
PMCPMC8329234
OpenAlexW3192291265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.